Pegunigalsidase-alfa

DRUG2 trials

Sponsors

Universität Münster, Chiesi Farmaceutici S.p.A.

Conditions

Fabry Disease

Unknown Phase

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

Active, not recruitingNCT06095713

Universität MünsterFabry Disease

Start: 2023-10-01End: 2027-09-30Updated: 2026-04-30

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

RecruitingNCT06663358

Chiesi Farmaceutici S.p.A.Fabry Disease

Start: 2024-11-06End: 2029-11-30Target: 100Updated: 2025-11-14